Does Medica Cover Metformin?

What Medica Is and Why Formulary Placement Matters

Medica is a nonprofit regional health insurer headquartered in Minnetonka, Minnesota, serving members primarily in Minnesota, Wisconsin, North Dakota, South Dakota, Nebraska, Iowa, and Kansas. The company offers commercial employer plans, individual and family marketplace plans, Medicare Advantage (MA) plans, and Medicaid managed care products.

Formulary placement determines how much a member pays for a prescription. Medica uses a multi-tier structure in most products. Tier 1 drugs are preferred generics and carry the lowest cost-sharing. Tier 2 drugs are non-preferred generics or preferred brands. Tier 3 and above include non-preferred brands and specialty drugs. Because metformin lost patent exclusivity decades ago, generic manufacturers now produce it at commodity prices, and payers routinely slot it at Tier 1. The FDA first approved metformin hydrochloride immediate-release tablets in 1994 for glycemic management in adults with type 2 diabetes, later extended to pediatric patients aged 10 and older. [1]

Metformin works primarily by suppressing hepatic glucose production through inhibition of mitochondrial complex I, reducing fasting plasma glucose without causing hypoglycemia on its own. [2] That favorable safety profile has made it the default first-line oral agent in every major diabetes guideline for more than two decades. [3]

The American Diabetes Association Standards of Care in Diabetes 2024 state: "Metformin remains the preferred initial pharmacologic agent for the treatment of type 2 diabetes." [3] Because it is listed as a preferred agent in ADA, AACE, and ACC/AHA cardiovascular risk-reduction guidelines, commercial insurers including Medica have strong incentives to keep it accessible at Tier 1.

How Medica Specifically Lists Metformin on Its Formularies

Generic metformin immediate-release (500 mg, 850 mg, and 1 to 000 mg tablets) sits at Tier 1 on essentially every Medica commercial plan formulary reviewed for 2024 and 2025. That typically means a $0 to $10 copay for a 30-day supply at in-network preferred pharmacies such as Walgreens, CVS, and most independent pharmacies in the Medica network. [4]

Metformin extended-release (500 mg and 750 mg tablets, sold generically and previously as Glucophage XR and Fortamet) is usually placed at Tier 2 on Medica plans. Tier 2 copays range from approximately $20 to $40 for a 30-day supply depending on the specific plan design. A small number of high-deductible health plans (HDHPs) require the member to meet the deductible before any drug cost-sharing applies, so early in the plan year the member pays the plan's negotiated rate rather than the flat copay. [5]

Branded Glucophage (metformin immediate-release by Bristol-Myers Squibb) is not actively manufactured for commercial sale in the United States as of 2024 and is listed as non-formulary or excluded on most Medica plans. If a prescriber requests it by brand name, the pharmacy will almost always dispense the generic unless a dispense-as-written (DAW) code is applied. In DAW situations on a non-covered brand, the member could pay full cash price.

The Medicare Advantage formulary situation differs slightly. Under the Part D standard benefit structure, generic metformin is typically placed in the Tier 1 or Tier 2 "preferred generic" or "generic" cost-sharing level. [6] CMS requires all Part D plans to cover metformin because it is on the CMS protected-class list for diabetes drugs and is explicitly recommended by CMS formulary guidance. [6]

Prior Authorization Requirements for Metformin Through Medica

Prior authorization (PA) is generally not required for generic metformin immediate-release on Medica commercial plans or Medicare Advantage products. [4] The drug's low cost and first-line status remove the financial justification for placing utilization management restrictions on it.

Metformin extended-release at doses above 2 to 000 mg/day may trigger a quantity limit review on certain Medica plans because the FDA-approved maximum labeled dose is 2 to 550 mg/day for immediate-release and 2 to 000 mg/day for most extended-release formulations. [1] Prescriptions written for quantities exceeding those limits may require a brief clinical note from the provider confirming medical necessity.

Step therapy (also called "fail-first") does not typically apply to metformin because it is the first-line agent. Step therapy is more commonly applied in reverse: a plan may require a trial of metformin before approving a more expensive agent such as semaglutide (Ozempic) or tirzepatide (Mounjaro). AACE guidelines explicitly place metformin as the initial agent in most type 2 diabetes algorithms unless contraindicated. [7]

The one scenario where PA may come up involves metformin prescribed off-label for polycystic ovary syndrome (PCOS) or for pre-diabetes prevention. The FDA has not approved metformin for PCOS, though it is widely used off-label based on evidence from trials such as the Diabetes Prevention Program (DPP, N=3,234), in which metformin 850 mg twice daily reduced diabetes incidence by 31% relative to placebo over 2.8 years. [8] Some Medica commercial plans may limit coverage to the FDA-approved type 2 diabetes indication, meaning a PCOS or pre-diabetes claim could be processed differently depending on the diagnosis code submitted by the prescriber.

Metformin Dosing, Formulations, and Which Version Medica Covers Best

The standard starting dose for adults with type 2 diabetes is metformin 500 mg once or twice daily with meals, titrated over 4 to 8 weeks to the effective dose, which for most patients is 1 to 500 mg to 2 to 000 mg per day. [3] The maximum dose is 2 to 550 mg/day for immediate-release. Extended-release is dosed once daily with the evening meal, and maximum labeled dosing is 2 to 000 mg/day for Glucophage XR-generics.

From a Medica coverage standpoint:

• Metformin IR 500 mg, 850 mg, 1 to 000 mg: Tier 1, no PA, preferred.
• Metformin ER 500 mg, 750 mg: Tier 2 on most plans, no PA within labeled quantity limits.
• Metformin oral solution 500 mg/5 mL: Less commonly stocked; may be Tier 2 or require PA depending on plan.
• Branded Glucophage, Glumetza, Fortamet: Non-formulary on most Medica plans; cash price applies unless a medical necessity exception is granted.

The gastrointestinal (GI) side effects of immediate-release metformin (nausea, diarrhea, abdominal cramps) affect roughly 20 to 30% of new users and are the leading cause of discontinuation. [9] Switching to the extended-release formulation reduces GI events in many patients. A 2016 randomized crossover study found that metformin ER produced significantly fewer GI adverse events compared with IR at equivalent doses. [9] If a patient needs ER for tolerability and faces the higher Tier 2 copay, most Medica plans allow an appeal or a prescriber's statement of medical necessity to maintain coverage.

Metformin Safety Considerations Relevant to Coverage Decisions

The FDA added a contraindication to metformin labels in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² due to risk of lactic acidosis. [1] For patients with eGFR between 30 and 45 mL/min/1.73 m², the FDA recommends caution and dose adjustment. [1] This renal threshold is not a formulary restriction but does affect clinical appropriateness. A Medica plan will still cover metformin for a patient with an eGFR of 25 mL/min/1.73 m² if it is prescribed, but the dispensing pharmacist may flag the contraindication.

Metformin reduces vitamin B12 absorption over time. A study published in Diabetes Care found that patients taking metformin for more than 4 years had a 19% reduction in serum B12 levels compared with non-users, with 5.8% developing frank deficiency. [10] Annual B12 monitoring is recommended by the ADA for long-term metformin users. [3]

The lactic acidosis risk is real but rare: approximately 3 cases per 100,000 patient-years in post-marketing surveillance. [11] Most cases involve concomitant renal or hepatic impairment, sepsis, or contrast media use. The FDA revised its labeling in 2016 to shift from a blanket renal contraindication to the eGFR-based threshold, expanding access for millions of patients with mild-to-moderate chronic kidney disease. [1]

Metformin for Longevity and Anti-Aging: What Coverage May Look Like

Interest in metformin as a longevity drug has grown significantly since observational data suggested diabetic patients on metformin lived longer than non-diabetic controls not taking any drug, a finding that prompted the design of the Targeting Aging with Metformin (TAME) trial. [12] TAME, funded by the American Federation for Aging Research, is enrolling approximately 3,000 adults aged 65 to 79 without diabetes at 14 U.S. sites to test whether metformin 1 to 500 mg/day delays a composite of aging-related outcomes. [12]

Mechanistically, metformin activates AMP-activated protein kinase (AMPK), inhibits mTORC1 signaling, and reduces insulin-like growth factor 1 (IGF-1) levels, all pathways implicated in biological aging and studied extensively in model organisms. [13] A 2020 analysis of the UK Biobank (N=41,204 metformin users) found that metformin use was associated with a 4% lower all-cause mortality hazard ratio (HR 0.96 to 95% CI 0.93 to 0.99) after adjustment for diabetes severity. [14]

Because metformin is not FDA-approved for longevity or anti-aging indications, Medica will not cover a prescription written solely with a longevity diagnosis code. The prescription must carry an ICD-10 code consistent with an approved indication, most commonly E11.xx (type 2 diabetes mellitus) or, in some plans, R73.09 (pre-diabetes with PA). A prescription written by a longevity or functional medicine physician for a non-diabetic patient may be rejected at the pharmacy or require a coverage exception. [4]

The cash price for generic metformin at GoodRx-contracted pharmacies is approximately $4 to $12 for a 30-day supply of 1 to 000 mg/day regardless of insurance, meaning longevity-focused patients without a covered diagnosis often pay less out-of-pocket by bypassing insurance entirely.

How to Verify Your Specific Medica Plan Covers Metformin

Medica's online formulary lookup tool is available at medica.com under "Find a Drug." Members enter their plan name or group number, then search metformin to see the exact tier, copay, and any quantity limits or step therapy requirements. This tool is updated when formularies change, typically on January 1 of each plan year, though mid-year formulary changes are permitted with 60-day advance notice under CMS Part D rules. [6]

If the online tool shows metformin as not covered or at an unexpectedly high tier, the member or prescriber should:

1. Confirm the correct plan name. Medica markets multiple products (Medica Choice, Medica with Optum, Medica HealthCare) with separate formularies.
2. Request a formulary exception by submitting a prescriber's letter explaining medical necessity.
3. Contact Medica member services at the number on the back of the insurance card to request an expedited formulary exception, which must be resolved within 72 hours under CMS rules for Part D. [6]
4. Ask the prescriber to submit the claim with the correct ICD-10 code.

Pharmacists can also run a real-time test claim through the pharmacy benefits manager (PBM) software to see exactly what the plan will pay and what the member owes before the prescription is filled. This takes under 30 seconds and costs nothing.

Comparing Metformin Coverage to Other Diabetes Drugs on Medica

The cost difference between metformin and newer diabetes agents on Medica plans is substantial. As of 2025:

• Generic metformin 1 to 000 mg/day: Tier 1, estimated $0 to $10/month.
• Generic glipizide or glimepiride (sulfonylureas): Tier 1, estimated $5 to $15/month.
• Jardiance (empagliflozin, SGLT-2 inhibitor): Tier 2 or 3, estimated $45 to $90/month after copay, often with PA.
• Ozempic (semaglutide 0.5 to 2 mg injectable): Tier 3 or specialty, estimated $25 to $200+/month with PA; list price exceeds $900/month without insurance.
• Mounjaro/Zepbound (tirzepatide): Specialty tier, PA required; copay varies widely.

The UKPDS trial (N=5,102) demonstrated that metformin reduced all-cause mortality by 36% and myocardial infarction by 39% in overweight patients with newly diagnosed type 2 diabetes compared with conventional diet therapy. [15] That mortality data, published in The Lancet in 1998, anchored metformin as the cornerstone agent and is directly responsible for its preferred-formulary status across all major U.S. insurers including Medica.

Empagliflozin has demonstrated cardiovascular mortality reduction in the EMPA-REG OUTCOME trial (HR 0.62 to 95% CI 0.49 to 0.77 for cardiovascular death), [16] and ADA guidelines now recommend adding an SGLT-2 inhibitor or GLP-1 receptor agonist in patients with established cardiovascular disease or high cardiovascular risk regardless of HbA1c. [3] Medica covers these agents but at higher tiers, reflecting their higher acquisition cost and the evidence that metformin should still be used as the background agent whenever tolerated.

What to Do If Medica Denies Metformin Coverage

Denials for generic metformin IR are rare but can happen if the diagnosis code is missing or incorrect, the prescriber's NPI is not recognized, or the prescription was transmitted to the wrong plan (e.g., a dental plan instead of the medical/pharmacy plan). Steps to resolve:

Step 1. Ask the pharmacist to identify the specific rejection code. Common codes include 75 (prior authorization required), 70 (product not on formulary), and 76 (plan limitations exceeded). Each has a different resolution path.

Step 2. Have the prescriber resubmit with the correct ICD-10 code. Type 2 diabetes coded as E11.9 is the most broadly accepted diagnosis for metformin.

Step 3. File a formal coverage determination request through Medica. Under CMS Part D rules, standard requests must be resolved within 72 hours; expedited (urgent) requests within 24 hours. [6]

Step 4. If the coverage determination is adverse, file a Level 1 appeal. Medica must respond to a standard Level 1 appeal within 7 days for a Part D drug. [6]

Step 5. If still denied, the Independent Review Entity (IRE) appointed by CMS handles Level 2 appeals for Medicare Advantage members, and state insurance commissioner offices handle commercial plan appeals in Minnesota and other states where Medica operates.

For patients who cannot wait, the cash price at Costco Pharmacy for 60 tablets of metformin 1 to 000 mg is approximately $6 to $9 without any discount card. GoodRx and Mark Cuban's Cost Plus Drugs (costplusdrugs.com) list metformin at similar prices. These are not Medica-covered transactions but serve as a bridge while an appeal is pending.

Metformin Access in Context: The Broader Clinical Picture

The DPP Outcomes Study (DPPOS), the 15-year follow-up of the original Diabetes Prevention Program, found that metformin 850 mg twice daily reduced diabetes incidence by 17 to 18% compared with placebo even at 15-year follow-up, a durable effect no other oral agent has matched in a randomized prevention trial. [8] The DPPOS also found a 49% lower incidence of microvascular complications in the metformin group compared with placebo at 15 years. [8]

These data explain why coverage access matters clinically. A 2019 analysis in JAMA Internal Medicine found that out-of-pocket cost increases of $10 per month were associated with a 22% higher rate of medication non-adherence for oral diabetes drugs. [17] Keeping metformin at Tier 1 with $0 to $10 copays directly affects whether patients take it as prescribed.

Medication adherence to metformin in real-world practice is approximately 50 to 60% at 12 months without active clinical support. [18] Programs that combine low-cost access with pharmacist counseling achieve adherence rates closer to 80%. [18] Medica members who use Medica pharmacy care management programs may qualify for additional adherence support at no additional cost.

The FDA-approved prescribing information for metformin states that the drug "should not be initiated in patients 80 years of age or older unless measurement of creatinine clearance demonstrates that renal function is not reduced," a caution relevant to Medicare Advantage members. [1] Medica's Medicare Advantage plans cover metformin at low cost but pharmacists are expected to flag this prescribing note for elderly members.